Mingxing Huang1,2, Yusheng Jie1, Guoli Lin1, Hong Shi1, Xinhua Li1, Xiangyong Li1, Yuankai Wu1, Yutian Chong3. 1. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, No. 600, Tianhe Road, Guangzhou, Guangdong, 510630, China. 2. Department of Infectious Diseases, Fifth Affiliated Hospital of Sun Yat-Sen University, Zhuhai, Guangdong, China. 3. Department of Infectious Diseases, Third Affiliated Hospital of Sun Yat-Sen University, No. 600, Tianhe Road, Guangzhou, Guangdong, 510630, China. chongyutian_1980@163.com.
Abstract
BACKGROUND AND OBJECTIVES: Tenofovir disoproxil fumarate (TDF) therapy is a therapeutic option for nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV). In this study, we evaluated the efficacy of TDF alone compared with the efficacy of TDF plus additional NA combinations in NA-experienced CHB patients. METHODS: This retrospective cohort study included 108 patients with a serum HBV DNA level above 5.0 log10 IU/ml who were treated with TDF alone (monotherapy group) or TDF combined with additional NAs (combination therapy group) for 30 months. RESULTS: At month 30, both therapies resulted in the suppression of HBV DNA levels: 66 of 66 patients (100 %) in the monotherapy group and 40 of 42 patients (95.23 %) in the combination therapy group achieved virologic suppression. Kaplan-Meier curves revealed median times for virologic suppression of 3.12 months in the monotherapy group and 5.23 months in the combination therapy group (p = 0.699). The probability of virologic suppression was comparable between treatment groups. At month 6, more patients achieved normal alanine aminotransferase (ALT) levels in the monotherapy group (p = 0.029). During the treatment period, no patients experienced severe renal dysfunction. CONCLUSION: TDF monotherapy and TDF plus additional NAs have comparable antiviral efficacy in CHB patients after NA treatment failure.
BACKGROUND AND OBJECTIVES:Tenofovir disoproxil fumarate (TDF) therapy is a therapeutic option for nucleos(t)ide analogue (NA)-experienced chronic hepatitis B (CHB) patients infected with hepatitis B virus (HBV). In this study, we evaluated the efficacy of TDF alone compared with the efficacy of TDF plus additional NA combinations in NA-experienced CHB patients. METHODS: This retrospective cohort study included 108 patients with a serum HBV DNA level above 5.0 log10 IU/ml who were treated with TDF alone (monotherapy group) or TDF combined with additional NAs (combination therapy group) for 30 months. RESULTS: At month 30, both therapies resulted in the suppression of HBV DNA levels: 66 of 66 patients (100 %) in the monotherapy group and 40 of 42 patients (95.23 %) in the combination therapy group achieved virologic suppression. Kaplan-Meier curves revealed median times for virologic suppression of 3.12 months in the monotherapy group and 5.23 months in the combination therapy group (p = 0.699). The probability of virologic suppression was comparable between treatment groups. At month 6, more patients achieved normal alanine aminotransferase (ALT) levels in the monotherapy group (p = 0.029). During the treatment period, no patients experienced severe renal dysfunction. CONCLUSION:TDF monotherapy and TDF plus additional NAs have comparable antiviral efficacy in CHB patients after NA treatment failure.
Authors: S J Patterson; J George; S I Strasser; A U Lee; W Sievert; A J Nicoll; P V Desmond; S K Roberts; S Locarnini; S Bowden; P W Angus Journal: Gut Date: 2010-10-29 Impact factor: 23.059
Authors: Patrick Marcellin; Edward Gane; Maria Buti; Nezam Afdhal; William Sievert; Ira M Jacobson; Mary Kay Washington; George Germanidis; John F Flaherty; Raul Aguilar Schall; Jeffrey D Bornstein; Kathryn M Kitrinos; G Mani Subramanian; John G McHutchison; E Jenny Heathcote Journal: Lancet Date: 2012-12-10 Impact factor: 79.321
Authors: Jurriën G P Reijnders; Katja Deterding; Jörg Petersen; Fabien Zoulim; Teresa Santantonio; Maria Buti; Florian van Bömmel; Bettina E Hansen; Heiner Wedemeyer; Harry L A Janssen Journal: J Hepatol Date: 2010-02-04 Impact factor: 25.083
Authors: Andrea Snow-Lampart; Brandi Chappell; Maria Curtis; Yuao Zhu; Florence Myrick; James Schawalder; Kathryn Kitrinos; Evguenia S Svarovskaia; Michael D Miller; Jeff Sorbel; Jenny Heathcote; Patrick Marcellin; Katyna Borroto-Esoda Journal: Hepatology Date: 2010-12-22 Impact factor: 17.425
Authors: Thomas Berg; Fabien Zoulim; Bernd Moeller; Huy Trinh; Patrick Marcellin; Sing Chan; Kathryn M Kitrinos; Phillip Dinh; John F Flaherty; John G McHutchison; Michael Manns Journal: J Hepatol Date: 2013-12-01 Impact factor: 25.083